The clinical significance of our work can be summarized as (1) the identified two potential biomarkers, i.e., IRF9 and XRCC1, had significant expression difference between PsP and TTP groups, demonstrating the two genes can distinguish the PsP and TTP; and (2) the identified biomarkers were most associated with the longitudinal imaging features, which reflected the development of PsP and TTP, and their biological functions were mainly involved in the tumor suppression, tumor prevention, and inflammation. This evidence concerns the gene XRCC1 and thrombotic thrombocytopenic purpura.